Ovarian Cancer

Anurag Singh, MD, and Emese Zsiros, MD, PhD, FACOG, are among the Roswell Park doctors finding innovative ways to improve patients’ quality of life without sacrificing effective cancer treatment.
An ovarian cancer test, CA125 is a reliable tool when used correctly. That is the message from Roswell Park following an FDA alert regarding the use of this common blood test.
“I owe my life to Roswell, and I give my doctors all the credit. For some reason, cancer likes my body, but I have to get through this. I don’t have any other choice."
Angela Eschrich, 64, and her daughter, Ashley, 36, have a lot in common. They both have boundless energy, stunning blue eyes, incredible courage and optimism, and — unbeknownst to them until two years ago — a BRCA2 gene mutation that greatly increases their risk of getting cancer.
“Before you begin treatment, you should feel good knowing that you have done your due diligence, you are confident that you have received the correct diagnosis, and you are comfortable with your medical team and your treatment plan,” says Dr. Frederick.
While your risk for developing uterine cancer is dramatically lowered by the surgery, your risk for other gynecologic cancers — such as ovarian — may not be.
Survivorship and quality-of-life programs to help patients regain physical, emotional and spiritual health are an important part of cancer care. One area that experts say deserves greater attention — restoring sexual health — is the focus of a clinic specifically for women at Roswell Park.
A second opinion at Roswell Park led to an immunotherapy clinical trial that gave ovarian cancer patient Julia Falleti more time with her family.
What matters most in terms of whether ovarian cancer will recur is the stage of disease at the time of diagnosis and if all visible cancer was removed at the time of surgery.
Dr. Clinton willingly traveled from Ohio to Buffalo every month, and sometimes more often, because the clinical trial “was the most advanced immunological treatment for my genetic type of cancer.

One of the biggest challenges in treating ovarian cancer is the fact that most women are not diagnosed until the cancer has already advanced and five-year survival is around 30%. By contrast, early-stage disease is highly treatable, with a survival rate of 90%.

I have never met them, nor have I ever thanked them for their part in my survival. And yet so much of that day and my treatment in the following months depended on their expertise.